CLEC2D

CLEC2D Full Name

C-type lectin domain family 2, member D

CLEC2D Introduction

C-type lectin domain family 2 member D (CLEC2D), also designated as lectin-like transcript 1 (LLT1) or osteoclast inhibitory lectin (OCIL), is a type II transmembrane protein belonging to the natural killer (NK) cell receptor-like C-type lectin family. Encoded by the CLEC2D gene located on human chromosome 12p13.31 within the natural killer gene complex (NKC), CLEC2D is expressed on a broad range of cell types including activated B cells, dendritic cells, osteoblasts, and several tumor cell lines. It functions as a ligand for the NK cell inhibitory receptor CD161 (NKR-P1A), participating in the regulation of innate and adaptive immune responses.

Figure 1. CLEC2D: structure, expression and immunomodulatory functions.

CD161-CLEC2D Immune Regulatory Axis
The interaction between CLEC2D and its cognate receptor CD161 represents an important immune checkpoint pathway. CD161 is expressed on NK cells, NKT cells, subsets of CD4+ and CD8+ T cells, and Th17 cells. CLEC2D engagement of CD161 delivers an inhibitory signal to NK cells, dampening their cytotoxic activity and cytokine production. This receptor-ligand pair functions analogously to classical MHC class I-KIR interactions but operates independently of antigen presentation. In the context of T cells, the CLEC2D-CD161 interaction modulates TCR-mediated signaling thresholds, influencing T cell activation and differentiation, particularly the balance between Th17 and regulatory T cell responses.

Oncoimmunological Significance and Therapeutic Potential
CLEC2D is overexpressed in several malignancies, including glioblastoma, non-Hodgkin lymphoma, and prostate cancer, where its engagement of CD161 on tumor-infiltrating lymphocytes contributes to an immunosuppressive tumor microenvironment. High CLEC2D expression has been correlated with poor clinical prognosis in certain cancer types. Conversely, in the bone microenvironment, CLEC2D (as OCIL) inhibits osteoclast differentiation and bone resorption by interfering with RANKL signaling, suggesting a protective role in bone homeostasis. Therapeutic strategies targeting the CLEC2D-CD161 axis, including blocking monoclonal antibodies and soluble receptor decoys, are being explored to enhance anti-tumor immunity while preserving bone integrity in cancer patients with skeletal involvement.

Alternate Names for CLEC2D

CLEC2D; C-type lectin domain family 2; member D; CLAX; LLT1; OCIL; C-type lectin domain family 2 member D; LLT-1; C-type lectin related f; lectin-like transcript 1; lectin-like NK cell receptor; osteoclast inhibitory lectin; C-type lectin superfamily 2; member D; anti-LLT1